Clinical trials

Condition   Drug Name  
Study 12B75 in psoriasis: The NCT00267969 study
Design Randomized; Double-blind; Multicenter
Patients 750
Treatment Regimen 12B75, 45 mg s.c. on wk 0 & 4 --> 1x/12 wks --> [if response] 1x/8 wks; 12B75, 90 mg s.c. on wk 0 & 4 --> 1x/12 wks --> [if response] 1x/8 wks; Placebo
Conclusions A phase III study will determine the safety and efficacy of 12B75 in patients with plaque-type psoriasis
Reference(s) A study of the safety and efficacy of CNTO 1275 in patients with severe plaque-type psoriasis (NCT00267969)
ClinicalTrials.gov Web Site 2007